Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28211098 | 0.84 | MAPT (0.57) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL10385139 | 0.80 | KMT2A (0.53) | ALDH1A1KMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL7871383 | 0.79 | MEN1 (0.46) | ALDH1A1KMT2AMEN1RAB9AMAPK1 | |
| SCHEMBL28879978 | 0.77 | ALDH1A1 (0.72) | ALDH1A1KMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL6217152 | 0.76 | ALDH1A1 (0.69) | ALDH1A1KMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL6217154 | 0.76 | ALDH1A1 (0.69) | ALDH1A1KMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL5340030 | 0.76 | MEN1 (0.89) | ALDH1A1KMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL7768635 | 0.76 | ALDH1A1 (0.66) | ALDH1A1KMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL30478066 | 0.76 | ALDH1A1 (0.66) | ALDH1A1KMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL474709 | 0.76 | KMT2A (0.70) | ALDH1A1KMT2AMEN1SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815852-B2 | Carbamoyloxy arylalkan arylpiperazine analgesics | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-08-26 | — | — | US | disclosed |
| EP-2150550-B1 | NOVEL CARBAMOYLOXY ARYL ALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-02-27 | — | — | EP | disclosed |
| US-20120095007-A2 | CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE ANALGESICS | SK HOLDINGS CO. LTD. (KR) | 2012-04-19 | — | — | US | disclosed |
| EP-2150550-A1 | NOVEL CARBAMOYLOXY ARYL ALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK Holdings Co., Ltd. (KR) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008140197-A1 | NOVEL CARBAMOYLOXY ARYL ALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK HOLDINGS CO., LTD. (KR) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095007-A2 | CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE ANALGESICS | OPRL1, OPRD1, TRPV1 | ALDH1A1 257/4885KMT2A 2621/4885MEN1 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.